In vivo reduction of hepatitis B virus antigenemia and viremia by antisense oligonucleotides

Journal of Hepatology

Volumn 64, Issue 4, 2016, Pages 781-789

  Billioud, Gaetan ^a   Kruse, Robert L ^d   Carrillo, Melissa ^a   Whitten Bauer, Christina ^a   Gao, Dacao ^b   Kim, Aneeza ^b   Chen, Leon ^d   McCaleb, Michael L ^b   Crosby, Jeffrey R ^b   Hamatake, Robert ^c   Hong, Zhi ^c   Garaigorta, Urtzi ^a   Swayze, Eric ^b   Bissig, Karl Dimiter ^d   Wieland, Stefan ^a,e  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b ISIS PHARMACEUTICALS   (United States)

^c GLAXOSMITHKLINE   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

2 MOE antisense molecule; HBV Infection; HBV transgenic mice; Hydrodynamic transfection

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CIRCULAR COVALENTLY CLOSED DNA; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; UNCLASSIFIED DRUG; VIRUS DNA; HEPATITIS B(E) ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; GENE EXPRESSION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HYDRODYNAMICS BASED TRANSFECTION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIREMIA; VIRUS GENE; ANIMAL; BLOOD; HEP-G2 CELL LINE; HEPATITIS B, CHRONIC; VIROLOGY;

ANIMALS; HEP G2 CELLS; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; MICE; OLIGONUCLEOTIDES, ANTISENSE; VIREMIA;

EID: 84956674107     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.11.032     Document Type: Article

References (58)

1. B. Custer, S.D. Sullivan, T.K. Hazlet, U. Iloeje, D.L. Veenstra, and K.V. Kowdley Global epidemiology of hepatitis B virus J Clin Gastroenterol 38 2004 S158 S168
2. D. Lavanchy Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures J Viral Hepat 11 2004 97 107
3. J.F. Perz, G.L. Armstrong, L.A. Farrington, Y.J. Hutin, and B.P. Bell The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide J Hepatol 45 2006 529 538
4. S. Urban, A. Schulze, M. Dandri, and J. Petersen The replication cycle of hepatitis B virus J Hepatol 52 2010 282 284
5. T. Nguyen, P. Desmond, and S. Locarnini The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B Hepatol Int 3 2009 5 15
6. S. Reignat, G.J. Webster, D. Brown, G.S. Ogg, A. King, S.L. Seneviratne, and et al. Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection J Exp Med 195 2002 1089 1101
7. F.V. Chisari, and C. Ferrari Hepatitis B virus immunopathogenesis Annu Rev Immunol 13 1995 29 60
8. D.R. Milich, J.E. Jones, J.L. Hughes, J. Price, A.K. Raney, and A. McLachlan Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc Natl Acad Sci U S A 87 1990 6599 6603
9. L.G. Guidotti, M. Isogawa, and F.V. Chisari Host-virus interactions in hepatitis B virus infection Curr Opin Immunol 36 2015 61 66
10. S. Liu, N. Peng, J. Xie, Q. Hao, M. Zhang, Y. Zhang, and et al. Human hepatitis B virus surface and e antigens inhibit major vault protein signaling in interferon induction pathways J Hepatol 62 2015 1015 1023
11. P. Marcellin, E. Gane, M. Buti, N. Afdhal, W. Sievert, I.M. Jacobson, and et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study Lancet 381 2013 468 475
12. S. Chevaliez, C. Hezode, S. Bahrami, M. Grare, and J.M. Pawlotsky Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely J Hepatol 58 2013 676 683
13. H. Jiang, J. Wang, and W. Zhao Lamivudine versus telbivudine in the treatment of chronic hepatitis B: a systematic review and meta-analysis Eur J Clin Microbiol Infect Dis 32 2013 11 18
14. G. Ebert, H. Poeck, J. Lucifora, N. Baschuk, K. Esser, I. Esposito, and et al. 5′ Triphosphorylated small interfering RNAs control replication of hepatitis B virus and induce an interferon response in human liver cells and mice Gastroenterology 141 2011 696 706 706, e691-e693
15. C.I. Wooddell, D.B. Rozema, M. Hossbach, M. John, H.L. Hamilton, Q. Chu, and et al. Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection Mol Ther 21 2013 973 985
16. T. Volz, L. Allweiss, M.M. Ben, M. Warlich, A.W. Lohse, J.M. Pollok, and et al. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus J Hepatol 58 2013 861 867
17. C.F. Bennett, and E.E. Swayze RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform Annu Rev Pharmacol Toxicol 50 2010 259 293
18. T.A. Vickers, S. Koo, C.F. Bennett, S.T. Crooke, N.M. Dean, and B.F. Baker Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis J Biol Chem 278 2003 7108 7118
19. Z.Q. Yao, Y.X. Zhou, A.L. Wang, X.F. Bai, and W.S. Yang Inhibition of hepatitis B viral gene expression by antisense phosphorothioate oligodeoxynucleotides J Viral Hepat 2 1995 85 89
20. K. Nakazono, Y. Ito, C.H. Wu, and G.Y. Wu Inhibition of hepatitis B virus replication by targeted pretreatment of complexed antisense DNA in vitro Hepatology 23 1996 1297 1303
21. B.E. Korba, and J.L. Gerin Antisense oligonucleotides are effective inhibitors of hepatitis B virus replication in vitro Antiviral Res 28 1995 225 242
22. S.H. Oh, B.I. Yeh, and S.H. Kim Inhibition of HBV replication by antisense oligodeoxyribonucleotides in HepG2 cells transfected with a cloned HBV DNA Yonsei Med J 36 1995 527 533
23. M. Reinis, M. Reinisova, E. Korec, and I. Hlozanek Inhibition of hepatitis B virus surface gene expression by antisense oligodeoxynucleotides in a human hepatoma cell line Folia Biol (Praha) 39 1993 262 269
24. G. Goodarzi, S.C. Gross, A. Tewari, and K. Watabe Antisense oligodeoxyribonucleotides inhibit the expression of the gene for hepatitis B virus surface antigen J Gen Virol 71 1990 3021 3025
25. Z.Q. Yao, Y.X. Zhou, J. Guo, Z.H. Feng, X.M. Feng, C.X. Chen, and et al. Inhibition of hepatitis B virus in vitro by antisense oligonucleotides Acta Virol 40 1996 35 39
26. Z.Q. Yao, Y.X. Zhou, X.M. Feng, and Z.X. Chen Specific inhibition of hepatitis b virus gene expression by an antisense oligonucleotide in vitro Acta Virol 39 1995 227 230
27. S.G. Park, S.M. Lee, and G. Jung Antisense oligodeoxynucleotides targeted against molecular chaperonin Hsp60 block human hepatitis B virus replication J Biol Chem 278 2003 39851 39857
28. X. Ding, J. Yang, and S. Wang Antisense oligonucleotides targeting abhydrolase domain containing 2 block human hepatitis B virus propagation Oligonucleotides 21 2011 77 84
29. X. Ding, F. Wang, M. Duan, J. Yang, and S. Wang Epiregulin as a key molecule to suppress hepatitis B virus propagation in vitro Arch Virol 154 2009 9 17
30. W. Xin, and J.H. Wang Treatment of duck hepatitis B virus by antisense poly-2′-O-(2,4-dinitrophenyl)-oligoribonucleotides Antisense Nucleic Acid Drug Dev 8 1998 459 468
31. P.N. Soni, D. Brown, R. Saffie, K. Savage, D. Moore, G. Gregoriadis, and et al. Biodistribution, stability, and antiviral efficacy of liposome-entrapped phosphorothioate antisense oligodeoxynucleotides in ducks for the treatment of chronic duck hepatitis B virus infection Hepatology 28 1998 1402 1410
32. W.B. Offensperger, S. Offensperger, and H.E. Blum Antisense therapy of hepatitis B virus infection Mol Biotechnol 9 1998 161 170
33. W.B. Offensperger, H.E. Blum, and W. Gerok Therapy of hepadnavirus infection using antisense oligonucleotides Intervirology 38 1995 113 119
34. M. Matsukura, K. Koike, and G. Zon Antisense phosphorothioates as antivirals against human immunodeficiency virus (HIV) and hepatitis B virus (HBV) Toxicol Lett 82-83 1995 435 438
35. Z. Yao, Y. Zhou, X. Feng, C. Chen, and J. Guo In vivo inhibition of hepatitis B viral gene expression by antisense phosphorothioate oligodeoxynucleotides in athymic nude mice J Viral Hepat 3 1996 19 22
36. S.J. Zheng, S. Zhong, J.J. Zhang, F. Chen, H. Ren, and C.L. Deng Distribution and anti-HBV effects of antisense oligodeoxynucleotides conjugated to galactosylated poly-L-lysine World J Gastroenterol 9 2003 1251 1255
37. T. Aboul-Fadl Antisense oligonucleotides: the state of the art Curr Med Chem 12 2005 2193 2214
38. G.Y. Wu, and C.H. Wu Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides J Biol Chem 267 1992 12436 12439
39. S.T. Crooke, and R.S. Geary Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B Br J Clin Pharmacol 76 2013 269 276
40. M.A. Sells, A.Z. Zelent, M. Shvartsman, and G. Acs Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions J Virol 62 1988 2836 2844
41. L.G. Guidotti, B. Matzke, H. Schaller, and F.V. Chisari High-level hepatitis B virus replication in transgenic mice J Virol 69 1995 6158 6169
42. E. Koller, T.M. Vincent, A. Chappell, S. De, M. Manoharan, and C.F. Bennett Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes Nucleic Acids Res 39 2011 4795 4807
43. R.S. Geary, E. Wancewicz, J. Matson, M. Pearce, A. Siwkowski, E. Swayze, and et al. Effect of dose and plasma concentration on liver uptake and pharmacologic activity of a 2′-methoxyethyl modified chimeric antisense oligonucleotide targeting PTEN Biochem Pharmacol 78 2009 284 291
44. L.G. Guidotti, V. Martinez, Y.T. Loh, C.E. Rogler, and F.V. Chisari Hepatitis B virus nucleocapsid particles do not cross the hepatocyte nuclear membrane in transgenic mice J Virol 68 1994 5469 5475
45. K.A. Sims, and A.M. Woodland Entecavir: a new nucleoside analog for the treatment of chronic hepatitis B infection Pharmacotherapy 26 2006 1745 1757
46. H. Yan, G. Zhong, G. Xu, W. He, Z. Jing, Z. Gao, and et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus Elife 1 2012 e00049
47. H. Kwon, and A.S. Lok Hepatitis B therapy Nat Rev Gastroenterol Hepatol 8 2011 275 284
48. C. Trepo, H.L. Chan, and A. Lok Hepatitis B virus infection Lancet 384 2014 2053 2063
49. M. Kawanaka, K. Nishino, J. Nakamura, T. Oka, N. Urata, D. Goto, and et al. Quantitative levels of hepatitis B virus DNA and surface antigen and the risk of hepatocellular carcinoma in patients with hepatitis B receiving long-term nucleos(t)ide analogue therapy Liver Cancer 3 2014 41 52
50. P. Arends, M.J. Sonneveld, R. Zoutendijk, I. Carey, A. Brown, M. Fasano, and et al. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians Gut 64 2014 1289 1295
51. Y. Kondo, M. Ninomiya, E. Kakazu, O. Kimura, and T. Shimosegawa Hepatitis B surface antigen could contribute to the immunopathogenesis of hepatitis B virus infection ISRN Gastroenterol 2013 2013 935295
52. S. Menne, C.A. Roneker, B.C. Tennant, B.E. Korba, J.L. Gerin, and P.J. Cote Immunogenic effects of woodchuck hepatitis virus surface antigen vaccine in combination with antiviral therapy: breaking of humoral and cellular immune tolerance in chronic woodchuck hepatitis virus infection Intervirology 45 2002 237 250
53. S. Menne, C.A. Roneker, B.E. Korba, J.L. Gerin, B.C. Tennant, and P.J. Cote Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection J Virol 76 2002 5305 5314
54. B. Weiss, G. Davidkova, and L.W. Zhou Antisense RNA gene therapy for studying and modulating biological processes Cell Mol Life Sci 55 1999 334 358
55. S. Carmona, M.R. Jorgensen, S. Kolli, C. Crowther, F.H. Salazar, P.L. Marion, and et al. Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles Mol Pharm 6 2009 706 717
56. X. Chen, Y. Qian, F. Yan, J. Tu, X. Yang, Y. Xing, and et al. 5′-triphosphate-siRNA activates RIG-I-dependent type I interferon production and enhances inhibition of hepatitis B virus replication in HepG2.2.15 cells Eur J Pharmacol 721 2013 86 95
57. M.G. Sebestyen, S.C. Wong, V. Trubetskoy, D.L. Lewis, and C.I. Wooddell Targeted in vivo delivery of siRNA and an endosome-releasing agent to hepatocytes Methods Mol Biol 1218 2015 163 186
58. D.V. Morrissey, J.A. Lockridge, L. Shaw, K. Blanchard, K. Jensen, W. Breen, and et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs Nat Biotechnol 23 2005 1002 1007